Novo Nordisk A/S KOPENHAGA: NOVO B, NYSE: NVO p. farmaceutyczny, producent m.in. insuliny, leków na hemofilię

[slayer74]

Novo Nordisk shares slump on obesity drug supply challenges

COPENHAGEN (Reuters) – Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.

COPENHAGEN (Reuters) -Novo Nordisk shares fell as much as 16% on Monday after the Danish drugmaker was hit by U.S. supply issues for its new obesity drug as it seeks to establish a market foothold before the launch of a rival drug by Eli Lilly.

https://www.fxempire.com/news/article/n ... rug-845579
...
Deutsche Bank Aktiengesellschaft Lowers Novo Nordisk A/S (NYSE:NVO) to Hold

Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a report issued on Friday, Analyst Price Targets reports.

NVO has been the subject of several other research reports. SEB Equities upgraded Novo Nordisk A/S from a hold rating to a buy rating in a research report on Monday, October 18th. Citigroup reiterated a buy rating on shares of Novo Nordisk A/S in a research report on Monday, August 23rd. UBS Group reiterated a neutral rating on shares of Novo Nordisk A/S in a research report on Thursday, November 11th. Bryan, Garnier & Co downgraded Novo Nordisk A/S from a buy rating to a sell rating and set a 592.00 price objective on the stock. in a report on Wednesday, November 3rd. Finally, Berenberg Bank reiterated a hold rating on shares of Novo Nordisk A/S in a report on Friday, September 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of Hold and a consensus price target of $341.50.

NYSE NVO opened at $107.45 on Friday. Novo Nordisk A/S has a 52 week low of $66.59 and a 52 week high of $117.35. The company has a quick ratio of 0.82, a current ratio of 1.03 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $109.49 and its 200-day simple moving average is $99.21. The firm has a market cap of $253.02 billion, a PE ratio of 33.47, a P/E/G ratio of 2.88 and a beta of 0.44.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, November 2nd. The company reported $5.27 earnings per share for the quarter, beating the consensus estimate of $0.78 by $4.49. Novo Nordisk A/S had a return on equity of 73.70% and a net margin of 34.33%. Research analysts expect that Novo Nordisk A/S will post 3.27 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP raised its stake in Novo Nordisk A/S by 345.8% during the 3rd quarter. Two Sigma Advisers LP now owns 715,900 shares of the company’s stock worth $68,734,000 after buying an additional 555,300 shares during the period. Amundi acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $45,181,000. Folketrygdfondet raised its stake in Novo Nordisk A/S by 11.0% during the 2nd quarter. Folketrygdfondet now owns 4,715,517 shares of the company’s stock worth $395,019,000 after buying an additional 466,107 shares during the period. Bank of Montreal Can raised its stake in Novo Nordisk A/S by 289.7% during the 2nd quarter. Bank of Montreal Can now owns 619,623 shares of the company’s stock worth $51,993,000 after buying an additional 460,625 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $37,246,000. 5.58% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

https://etfdailynews.com/news/deutsche- ... o-to-hold/

[slayer74]

Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Hold at Danske

Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at Danske from a “buy” rating to a “hold” rating in a report issued on Monday, The Fly reports.

Several other brokerages also recently commented on NVO. Citigroup restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, August 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Novo Nordisk A/S in a research note on Tuesday, November 2nd. Bryan, Garnier & Co cut Novo Nordisk A/S from a “buy” rating to a “sell” rating and set a 592.00 target price on the stock. in a research note on Wednesday, November 3rd. SEB Equities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, October 18th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, November 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $341.50.

Shares of NVO opened at $106.21 on Monday. The stock’s 50-day simple moving average is $109.76 and its 200 day simple moving average is $99.56. Novo Nordisk A/S has a 52-week low of $66.59 and a 52-week high of $117.35. The stock has a market capitalization of $250.10 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 2.72 and a beta of 0.44. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.03.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, November 2nd. The company reported $5.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $4.49. Novo Nordisk A/S had a return on equity of 73.70% and a net margin of 34.33%. On average, research analysts forecast that Novo Nordisk A/S will post 3.27 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Moors & Cabot Inc. grew its position in Novo Nordisk A/S by 233.9% during the 3rd quarter. Moors & Cabot Inc. now owns 8,728 shares of the company’s stock worth $836,000 after purchasing an additional 6,114 shares during the period. JB Capital LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $466,000. Patriot Financial Group Insurance Agency LLC grew its position in shares of Novo Nordisk A/S by 947.5% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 5,447 shares of the company’s stock valued at $523,000 after acquiring an additional 4,927 shares during the period. Fortis Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $29,000. Finally, EP Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 19.3% during the 3rd quarter. EP Wealth Advisors LLC now owns 4,217 shares of the company’s stock valued at $405,000 after acquiring an additional 683 shares during the period. 5.58% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

[slayer74]

Investing.com — Novo Nordisk A/S (NYSE:NVO) said Friday that it has settled a securities lawsuit in Denmark.

Shares of Novo fell 3% in midday trading.

The company said the settlement contained no admission of liability, wrongdoing or responsibility and Novo Nordisk is not making any payment.

The 2019 lawsuit alleged the company made misleading statements and did not make appropriate disclosures regarding its insulin business in the United States.

The lawsuit was filed by several shareholders claiming compensation worth 11.785 billion Danish crowns or approximately $1.75 billion.

At the time, Novo said it "disagrees with the allegations and is prepared to defend the company in this matter."

[slayer74]

Dawno tyle sesji spadkowych nie było

[slayer74]

Novo Nordisk A/S reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER).

Diabetes and Obesity care sales drove the increased sales as GLP-1 sales increased by 36% at CER. Obesity care sales increased by 73%, partially offset by decreased insulin sales by 1%. Biopharm sales increased by 6% at CER.
Novo reported a fourth-quarter operating profit of DKK 13.63 billion, an increase of 16% at CER over the corresponding period last year.
Related: FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report.
In December, a contract manufacturer halted deliveries and manufacturing temporarily after issues relating to good manufacturing practice.
Fewer new weekly patient initiations are expected in 1H of 2022 compared to Q4 FY21. Novo Nordisk still hopes to meet demand in the U.S. in 2H of 2022.
Share Buyback: The Board of Directors intends to initiate a new 12-month share repurchase program of up to DKK 22 billion.
Guidance: The company expects to generate sales growth of 6% - 10% and deliver operating profit growth of 4% - 8% at CER in 2022.
Price Action: NVO shares are up 3.89% at $106.60 on the last check Wednesday.

https://www.benzinga.com/general/biotec ... e-resolved

[slayer74]

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S NVO +0.06% (Get Free Alerts for NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk aims to generate annual obesity drug sales of more than DKK25 billion by 2025. Novo's diabetes and obesity sales leaped 15% to DKK121.6 billion in 2021. Obesity sales alone rose 55%.

Related: Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved.

The company had a breakthrough with Wegovy, which was released in the U.S. in June last year and helped achieve a weight loss of 17% on average over almost two years. Novo Nordisk was overwhelmed by initial demand for Wegovy, leading to supply shortages.

In December, the company took a further hit when Catalent Inc CTLT +0.01% temporarily halted deliveries and manufacturing after issues relating to good manufacturing practice.

Novo expects to meet demand in the second half of this year. Still, Novo remains confident it can meet U.S. demand for Wegovy in the second half of the year, the company said in Thursday's presentation.

Production is expected to kick off in the second quarter, with Novo's contract manufacturer planning to initiate media fill test runs "in the coming weeks." Novo said it expects to boost capacity for Wegovy in 2023.

Price Action: NVO shares are down 0.20% at $104.46 during the market session on the last check Thursday.

https://www.benzinga.com/general/biotec ... ovy-demand

[slayer74]

COPENHAGEN (Reuters) – Shares in Novo Nordisk jumped on Friday after the firm lifted its sales and operating profit guidance for the year on the back of forecast-beating first-quarter earnings, driven by strong sales of its newer diabetes and obesity treatments.

COPENHAGEN (Reuters) – Shares in Novo Nordisk jumped on Friday after the firm lifted its 2022 sales and operating profit guidance on the back of forecast-beating first-quarter earnings, driven by strong sales of its newer diabetes and obesity treatments.

Novo Nordisk now expects sales growth of 10-14% in local currencies, up from a previous estimate of 6-10%. It sees operating profit up 9-13%, versus an earlier forecast of 4-8%.

“Insanely strong start to the year by Novo Nordisk and a significant upward adjustment,” Jyske Bank analyst Henrik Laustsen said in a note.

Shares in Novo rose 6.5% at market open and were up 4% at 1015 GMT.

“We are very pleased with the sales growth in the first three months of 2022 which is driven by increasing demand for our GLP-1-based treatments,” CEO Lars Jorgensen said in a statement, referring to Novo’s newer diabetes and obesity drugs.

First-quarter operating profit came in at 19 billion Danish crowns ($2.69 billion), above the 17.2 billion crowns estimated by analysts, Refinitiv data showed.

Novo also said a contract manufacturer filling syringes for its promising Wegovy obesity drug had resumed commercial production, paving the way for Novo to make the drug fully available in the United States during the second half of 2022.

The manufacturer had temporarily halted deliveries and manufacturing in December after issues relating to good manufacturing practice.

High volume growth of Novo’s GLP-1-based products, including key diabetes drug Ozempic, could lead to periodic supply constraints, which was reflected in the new outlook, Novo said.

“We have seen some (supply issues), but none of them something that is material to Novo Nordisk,” Jorgensen told journalists on a media call.

Ozempic sales leapt 70% in local currencies in the first quarter to reach 12 billion crowns.

Novo will also expand its share repurchase programme by 2 billion Danish crowns to a total of 24 billion, it said.

[slayer74]

ATechniczna - nowy rekord wszechczasów

[slayer74]

Novo Nordisk (NYSE:NVO) stock rose 4.4% after the Danish drugmaker raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, while Straumann (SIX:STMN) stock rose 4% after the Swiss dental implants maker raised its 2022 organic sales growth outlook.

[slayer74]

Novo Nordisk (CSE:NOVOb) stock rose 0.4% after the Danish drug maker announced plans to expand its existing facilities in Bagsværd, Denmark, with the project expected to be finalized in 2024 and create about 160 new jobs.

[slayer74]

Novo Nordisk (NVO) won FDA approval to label its oral diabetes drug Rybelsus as a first-line treatment. That expands Novo’s lead in the segment. Pfizer (PFE) and Eli Lilly (LLY) aim to launch their own pills using the same mechanism.

[slayer74]

Rekord wszech czasów na zamk. 994 DKK, będzie jutro atak na 100 DKK?

[slayer74]

IBD 50 Growth Stock: Diabetes Breakthrough Lifts Denmark Drugmaker

VIDYA RAMAKRISHNAN02:43 PM ET 02/27/2023

Novo Nordisk (NVO) is building a flat base with a possible buy point at 144.88. The stock is positioned to grow from the recent FDA approval for a breakthrough oral drug for type 2 diabetes. NVO has joined the elite IBD 50 growth stock list.

This $326 billion Denmark-based pharmaceutical giant develops and markets therapies for diabetes, obesity, hormone replacement and growth disorders. It has also partnered with Lumen Bioscience for oral medicines to treat cardiometabolic disease.

It is on the fast track after the FDA approved Rybelsus, a revolutionary oral drug for type 2 diabetes, taking the lead from Pfizer (PFE) and Eli Lilly (LLY). This compound stimulates the hormone that regulates liver activity while improving insulin levels in the body.

Novo also plans to increase production of weight loss drug Wegovy, which has been in short supply in the U.S. According to reports, sales grew 300% in 2022 despite empty shelves.

NVO stock has impressive 94 Composite and Relative Strength Ratings. Steady sales growth over the past eight quarters highlights the stock's fundamental strength. Earnings have also grown over this period, except for a miss in one quarter, supporting the 83 Earnings Per Share Rating.

Strong Sales And Earnings Growth
Fourth-quarter sales of $6.9 million marked 18% year-over-year growth, while earnings rose 19% to 87 cents per share. FactSet analysts expect Q1 2023 sales to increase 11% year over year to $6.9 million, with earnings up 16% to$1.08 per share.

On Feb. 1, Novo rallied on news it will repurchase $798 million worth of shares between February and May of this year.

https://www.investors.com/research/grow ... akthrough/

The growth stock holds the top spot in the Medical-Ethical Drugs subsector, which ranks 92nd among IBD's 197 industry groups, according to IBD MarketSmith.


Growth Stock Enters NASH Competition
Last September, Novo bought Ventus Therapeutics for $70 million, taking charge of the lab's anti-inflammatory research for chronic kidney disease and other cardiometabolic disorders.

Earlier, it acquired IFM Therapeutics for $1.5 billion, accessing its portfolio of drugs for metabolic, autoimmune and neurological diseases. IFM also researches treatments for fatty liver diseases, for which there is no FDA-approved treatment yet.

More funds have been buying NOVO stock over the past seven quarters. Growing fund ownership is a sign of strength, according to the CAN SLIM trading methodology.

[slayer74]

Europe will lose out on medical innovation if draft EU reforms pass, Novo Nordisk CEO says

LONDON (Reuters) - Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape change, the CEO of Danish drugmaker Novo Nordisk (NYSE:NVO) warned on Thursday.

The European Commission will present its proposed overhaul of the bloc's pharmaceuticals regulation on March 29, the first major revisions to medicines rules in 20 years. It says drugs need to reach patients more quickly and in all European nations.

Novo's Lars Jorgensen lamented that without changes to the current draft, his company would be forced to research, test and bring products in its pipeline to market in the United States and elsewhere, instead of in Europe.

Novo is the world's biggest producer of diabetes drugs, and Jorgensen said that while the company shares the European Union's wish that patients across Europe have access to the same treatments, Brussels' proposal would delay access for Europe as a whole as companies like his would work elsewhere.

"You're not getting the health benefit and you're not getting the economic activity level from the industry, either. A lose, lose, lose," he said in an interview.

Consumer groups say the changes would make things fairer, for example by shaving off two years of exclusivity on new products unless companies introduce them simultaneously in all 27 member states.

The pharma industry, lobbying hard against parts of the draft, counters that this will introduce uncertainty over whether investment costs will be recouped before generic competition enters, while putting up regulatory hurdles that even the biggest companies will struggle to clear.

EU Health Commissioner Stella Kyriakides told Reuters on Thursday that any changes to the current system would "aim to strike the right balance" between equal access and promoting innovation "and a globally competitive EU industry".

The Commission's current draft was leaked in Brussels last month and will likely change even before debate in the European parliament and among governments.

Novo's Jorgensen said that in the U.S. there are already benefits like "fast" clearance to start clinical development and quicker approvals, plus ample venture capital funding for biotech, making it "the centre of gravity in science".

Such factors drove Novo's decision, announced on Thursday, to add 200 new jobs in the Boston area, creating one of its largest R&D hubs outside of Denmark.

However, Jorgensen said it was still not a "walk in the park" in the U.S., referring to the Inflation Reduction Act passed by Congress last year.

"But the ecosystem...is more attractive," he said.

For stem cell therapy for conditions such as type 1 diabetes, chronic heart failure and Parkinson's disease, one of Novo's priorities, the company is running new clinical trials in Japan and investing to expand its technological capacity in the U.S, rather than in Europe, Jorgensen said.

https://www.investing.com/news/stock-ma ... ys-3021088

[slayer74]

Novo Nordisk (NVO) continued hitting highs after inking a deal to develop new diabetes and
obesity treatments using Aspect Biosciences’ bio-printing capabilities. The Danish drug giant
also boosted its full-year outlook, citing better-than-expected sales of weight-loss drug Wegovy and diabetes med Ozempic.